☆ 4.6 Article

Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients

VIRUSES-BASEL (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients

Jose Luis Pinana et al.

Summary: This study examined the relationship between antibody response and SARS-CoV-2 infection in 1551 patients with hematological disorders after completing the full vaccine regimen. The results showed that 17% of the patients developed SARS-CoV-2 infection during the 388-day follow-up. Multivariate analysis identified higher incidence in chronic lymphocytic leukemia patients and those using corticosteroids.

BLOOD CANCER JOURNAL (2023)

添加到收藏夹

Article Biophysics

SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination

Jose Luis Pinana et al.

Summary: The study examined the kinetics of SARS-CoV-2 reactive IgG antibodies after full vaccination and booster in different stem cell transplantation and CAR-T therapy settings. The results showed a decline in antibody titers over time, especially in recipients without pre-vaccine infection. Booster doses were effective in increasing antibody titers in poorly responding allo-HSCT and ASCT recipients, but not in CAR-T cell recipients. Antibody levels were associated with breakthrough infection and disease severity. The study also identified immunosuppressive drugs and conditioning intensity as factors affecting the risk of breakthrough infection in allo-HSCT recipients.

BONE MARROW TRANSPLANTATION (2023)

添加到收藏夹

Article Infectious Diseases

Current outcomes of SARS-CoV-2 Omicron variant infection in high-risk haematological patients treated early with antivirals

Tommaso-Francesco Aiello et al.

Summary: This study aimed to describe the clinical outcomes and duration of viral shedding in high-risk patients with haematological malignancies hospitalized with COVID-19 during Omicron variant predominance who received early treatment with antivirals. The analysis included 60 consecutive adults with high-risk haematological malignancies and COVID-19. Overall, the current outcomes of high-risk patients with haematological malignancies hospitalized with COVID-19 during Omicron variant predominance are good with the use of early antiviral strategies, and persistent viral shedding is uncommon.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2023)

添加到收藏夹

Article Immunology

Improved outcomes over time and higher mortality in CMV seropositive allogeneic stem cell transplantation patients with COVID-19; An infectious disease working party study from the European Society for Blood and Marrow Transplantation registry

Per Ljungman et al.

Summary: This study reports on the incidence and mortality of COVID-19 in allogeneic hematopoietic stem cell transplant (allo-HCT) recipients. It found that patients who contracted COVID-19 within 30 days or 30-100 days after transplant and those who were older and had worse immune status were at higher risk. Despite improved outcomes, there are still risks associated with severe COVID-19 in this population.

FRONTIERS IN IMMUNOLOGY (2023)

添加到收藏夹

Article Chemistry, Medicinal

Bench-to-bedside: Innovation of small molecule anti-SARS-CoV-2 drugs in China

Liyan Yang et al.

Summary: The ongoing COVID-19 pandemic has highlighted the urgent need for potent prophylactic and therapeutic strategies against SARS-CoV-2. Small molecule inhibitors play a crucial role in the clinical treatment of SARS-CoV-2. China has made significant progress in the development of anti-SARS-CoV-2 drugs, but there is still limited knowledge regarding their pharmacological activity, antiviral mechanisms, and clinical efficacy. This review discusses the development of small molecule anti-SARS-CoV-2 drugs in China and summarizes their pharmacological activity, potential mechanisms of action, clinical trials and use, and important milestones in their discovery.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2023)

添加到收藏夹

Article Immunology

Upper and/or Lower Respiratory Tract Infection Caused by Human Metapneumovirus After Allogeneic Hematopoietic Stem Cell Transplantation

Jose Luis Piñana et al.

JOURNAL OF INFECTIOUS DISEASES (2023)

添加到收藏夹

Article Medicine, General & Internal

Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry

Jon Salmanton-Garcia et al.

Summary: Nirmatrelvir/ritonavir treatment is associated with lower mortality in hematological malignancy patients. The treatment is related to the presence of extra-pulmonary symptoms and vaccination status for COVID-19, but not chronic pulmonary disease or obesity.

ECLINICALMEDICINE (2023)

添加到收藏夹

Letter Oncology

Update of recommendations for the management of COVID-19 in patients with haematological malignancies, haematopoietic cell transplantation and CAR T therapy, from the 2022 European Conference on Infections in Leukaemia (ECIL 9)

Simone Cesaro et al.

LEUKEMIA (2023)

添加到收藏夹

Article Critical Care Medicine

COVID-19 bacteremic co-infection is a major risk factor for mortality, ICU admission, and mechanical ventilation

Michael John Patton et al.

Summary: A large retrospective study found that community-acquired bacterial co-infection related to COVID-19 is a significant factor contributing to mortality, with a higher mortality rate compared to community-acquired bacteremia. An elevated neutrophil-to-lymphocyte ratio above 15 is a prognostic indicator of COVID-19 bacterial co-infection.

CRITICAL CARE (2023)

添加到收藏夹

Letter Medicine, General & Internal

Potential Healthy Vaccinee Bias in a Study of BNT162b2 Vaccine against Covid-19

Tracy B. Hoeg et al.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

添加到收藏夹

Article Pharmacology & Pharmacy

Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern

Laura Vangeel et al.

Summary: Remdesivir and its parent nucleoside, molnupiravir and its parent nucleoside, and the viral protease inhibitor nirmatrelvir have equipotent antiviral activity against the ancestral SARS-CoV2 strain and the variants of concern including Omicron.

ANTIVIRAL RESEARCH (2022)

添加到收藏夹

Article Medicine, General & Internal

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

Jennifer Hammond et al.

Summary: In high-risk, unvaccinated adults, treatment of Covid-19 with nirmatrelvir plus ritonavir can significantly reduce the risk of hospitalization and death, with good safety profile.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Cell Biology

A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus

William A. Fischer et al.

Summary: In a clinical trial, the safety, tolerability, and antiviral efficacy of molnupiravir were evaluated in unvaccinated individuals with confirmed SARS-CoV-2 infection. The study found that participants receiving high-dose molnupiravir had a shorter time to viral RNA clearance and a lower detection rate of infectious virus. Molnupiravir was well tolerated across all doses.

SCIENCE TRANSLATIONAL MEDICINE (2022)

添加到收藏夹

Article Hematology

COVID-19 in patients with hematologic malignancy

Petra Langerbeins et al.

BLOOD (2022)

添加到收藏夹

Article Oncology

SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders

Jose Luis Pinana et al.

Summary: This study found that lack of detectable antibodies at 3-6 weeks after full vaccination was the main variable associated with breakthrough infection, and antibody titers above 250 BAU/mL significantly reduced the incidence and severity of the infection.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)

添加到收藏夹

Article Infectious Diseases

Corticosteroids and superinfections in COVID-19 patients on invasive mechanical ventilation

Signe Sovik et al.

Summary: Dexamethasone use in mechanically ventilated COVID-19 patients is strongly associated with superinfections, as well as pre-existing autoimmune disease and longer ICU stays. While superinfections do not impact 90-day survival, patients receiving dexamethasone have lower survival rates.

JOURNAL OF INFECTION (2022)

添加到收藏夹

Review Physiology

Co-infections in COVID-19 patients and correlation with mortality rate. Minireview

A. G. N. E. S. FEHER et al.

Summary: This review gathered information on the most common community-acquired and hospital-acquired co-infections among COVID-19 patients, identifying risk factors and outcomes associated with these co-infections. It found that bacterial and fungal co-infections were equally frequent, especially in hospital settings, with risk factors including male gender, longer hospital stays, and certain treatments. Co-infections were associated with increased disease severity and poorer outcomes.

PHYSIOLOGY INTERNATIONAL (2022)

添加到收藏夹

Article Hematology

Early administration of remdesivir plus convalescent plasma therapy is effective to treat COVID-19 pneumonia in B-cell depleted patients with hematological malignancies

Ferenc Magyari et al.

Summary: In this study, the combination of remdesivir and convalescent plasma therapy was found to be efficient and safe for the treatment of COVID-19 in patients with hematological malignancies and B-cell lymphopenia. This combined treatment reduced the need for oxygen support, length of hospital stay, and viral positivity.

ANNALS OF HEMATOLOGY (2022)

添加到收藏夹

Editorial Material Medicine, General & Internal

In patients with COVID-19 at risk for severe disease, nirmatrelvir plus ritonavir reduced hospitalization or death

Athanasios Vassilopoulos et al.

ANNALS OF INTERNAL MEDICINE (2022)

添加到收藏夹

Letter Infectious Diseases

Paxlovid in patients who are immunocompromised and hospitalised with SARS-CoV-2 infection

Fangfang Sun et al.

LANCET INFECTIOUS DISEASES (2022)

添加到收藏夹

Article Public, Environmental & Occupational Health

Sex differences in comorbidities and COVID-19 mortality-Report from the real-world data

Yilin Yoshida et al.

Summary: This study aims to examine the association between major comorbidities and COVID-19 mortality in men and women separately.

FRONTIERS IN PUBLIC HEALTH (2022)

添加到收藏夹

Letter Infectious Diseases

Paxlovid in patients who are immunocompromised and hospitalised with SARS-CoV-2 infection

Fangfang Sun et al.

LANCET INFECTIOUS DISEASES (2022)

添加到收藏夹

Review Medicine, General & Internal

Pathophysiological Basis and Rationale for Early Outpatient Treatment of SAKS-CoV-2 (COVID-19) Infection

Peter A. McCullough et al.

Summary: The global spread of SARS-CoV-2 over approximately 9 months has resulted in a rise in acute hospitalizations and deaths due to COVID-19. In the absence of clinical trial results, physicians must rely on existing knowledge of the pathophysiology of SARSCoV-2 infection to determine early outpatient treatment in order to prevent hospitalization or death.

AMERICAN JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Immunology

Seasonal Human Coronavirus Respiratory Tract Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation

Jose Luis Pinana et al.

Summary: This study on seasonal HCoVs after allo-HSCT found a high incidence of LRTD and higher mortality in critical cases, with absolute lymphocyte count, corticosteroid use, and ICU admission identified as factors associated with increased mortality in LRTD patients.

JOURNAL OF INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Oncology

COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey

Per Ljungman et al.

Summary: The study reveals that COVID-19 patients who have undergone allogeneic or autologous hematopoietic cell transplantation are at high risk of developing lower respiratory tract disease, requiring ICU admission, and have increased mortality rates.

LEUKEMIA (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Male gender is a predictor of higher mortality in hospitalized adults with COVID-19

Ninh T. Nguyen et al.

Summary: This study analyzed the characteristics and outcomes of male compared to female adults with COVID-19 in US academic centers. Males with COVID-19 showed higher rates of hypertension, diabetes, renal failure, heart failure, and liver disease, while females were more likely to be obese and have chronic pulmonary disease. Male COVID-19 patients had higher in-hospital mortality rates, higher rates of respiratory intubation, and longer hospital stays compared to females.

PLOS ONE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients

Jin-Lan Zhang et al.

Summary: FNC, a nucleoside analog, has shown activity against HIV-1 and SARS-CoV-2. Research suggests FNC's anti-viral effect is concentrated in the thymus, promoting immunity. Clinical trials have demonstrated oral FNC's ability to effectively cure COVID-19 patients.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)

添加到收藏夹

Article Medicine, General & Internal

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

Chenguang Shen et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

添加到收藏夹

Article Medicine, General & Internal

Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19)

J. Wu et al.

JOURNAL OF INTERNAL MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

Remdesivir for the Treatment of Covid-19-Final Report

John H. Beigel et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Editorial Material Medicine, Research & Experimental

Clinical trials for COVID-19 should include sex as a variable

Evelyne Bischof et al.

JOURNAL OF CLINICAL INVESTIGATION (2020)

添加到收藏夹

Letter Infectious Diseases

Viral dynamics in mild and severe cases of COVID-19

Yang Liu et al.

LANCET INFECTIOUS DISEASES (2020)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Higher mortality of COVID-19 in males: sex differences in immune response and cardiovascular comorbidities

Laura A. Bienvenu et al.

CARDIOVASCULAR RESEARCH (2020)

添加到收藏夹

Article Oncology

Risk factors and outcome of COVID-19 in patients with hematological malignancies

Jose Luis Pinana et al.

EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer

Victoria A. Avanzato et al.

CELL (2020)

添加到收藏夹

Letter Medicine, General & Internal

Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer

Teresa Aydillo et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission

Hannah Peckham et al.

NATURE COMMUNICATIONS (2020)

添加到收藏夹

Article Hematology

Human rhinovirus detection in the lower respiratory tract of hematopoietic cell transplant recipients: association with mortality

Sachiko Seo et al.

HAEMATOLOGICA (2017)

添加到收藏夹

Article Hematology

Human rhinovirus detection in the lower respiratory tract of hematopoietic cell transplant recipients: association with mortality

Sachiko Seo et al.

HAEMATOLOGICA (2017)

添加到收藏夹

Review Microbiology

Diagnostic Accuracy of Rapid Antigen Detection Tests for Respiratory Syncytial Virus Infection: Systematic Review and Meta-analysis

Caroline Chartrand et al.

JOURNAL OF CLINICAL MICROBIOLOGY (2015)

添加到收藏夹

Article Immunology

Parainfluenza Virus Lower Respiratory Tract Disease After Hematopoietic Cell Transplant: Viral Detection in the Lung Predicts Outcome

Sachiko Seo et al.

CLINICAL INFECTIOUS DISEASES (2014)

添加到收藏夹

Article Hematology

The characteristics and outcomes of parainfluenza virus infections in 200 patients with leukemia or recipients of hematopoietic stem cell transplantation

Roy F. Chemaly et al.

BLOOD (2012)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.